Hennion & Walsh Asset Management, Inc. Bio Xcel Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 40,099 shares of BTAI stock, worth $16,440. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,099
Previous 40,599
1.23%
Holding current value
$16,440
Previous $51,000
52.94%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$492,5640.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$180,6800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$122,1970.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$75,8730.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$53,2460.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $11.5M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...